News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|August 1, 2003

Infants' rapid weight gain risks adult obesity

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Q1 2026 recap: 6 FDA approvals pediatricians need to know | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

Q1 2026 recap: 6 FDA approvals pediatricians need to know

ByCeleste Krewson, Assistant Editor

March 31st 2026

Ashley Shoemaker, MD, MSci, discusses diagnosing rare genetic and hypothalamic obesity | Image Credit: pediatrics.vumc.org.

Ashley Shoemaker, MD, MSci, discusses diagnosing rare genetic and hypothalamic obesity

ByAshley Shoemaker, MD, MSci

March 25th 2026

Ashley Shoemaker, MD, MSci, discusses leveraging setmelanotide in acquired hypothalamic obesity | Image Credit: pediatrics.vumc.org.

Ashley Shoemaker, MD, MSci, discusses leveraging setmelanotide in acquired hypothalamic obesity

ByAshley Shoemaker, MD, MSci

March 25th 2026

Leveraging setmelanotide in acquired hypothalamic obesity, with Ashley Shoemaker, MD, MSci

Leveraging setmelanotide in acquired hypothalamic obesity, with Ashley Shoemaker, MD, MSci

ByAshley Shoemaker, MD, MSci

March 21st 2026

FDA Approves Setmelanotide for Acquired Hypothalmic Obesity in Ages 4 Years and Older | Credit: FDA

FDA approves setmelanotide for acquired hypothalmic obesity in patients 4 years and older

ByPatrick Campbell

March 20th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA approves centanafadine for ADHD in children, adolescents, and adults

Pooled phase 3 data show early, consistent tapinarof cream responses across pediatric age groups in AD

FDA approves acetaminophen-naproxen sodium combination tablet for ages 12 and older

Omalizumab outperforms multiallergen oral immunotherapy in multifood allergy trial

US measles cases surpass 2025 total, hit highest level since 1991